Event Group
Event Groups are part of the Adverse Events Module within the Results Section. They provide a way to organize and summarize adverse event data by grouping related events together.
Each Event Group typically represents a category or class of adverse events and includes statistical information such as the number of participants affected and at risk for different event types: deaths, serious events, and other events.
Event Group path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Group
Event Group
Ignite Creation Date:
2025-12-24 @ 6:36 PM
Ignite Modification Date:
2025-12-25 @ 4:06 PM
NCT ID:
NCT02953457
Group ID:
EG002
Title:
Phase II Treatment (Olaparib, Tremelimumab, Durvalumab) - Platinum Sensitive Patients
Description:
Durvalumab 1500 mg + Tremelimumab 75 mg + Olaparib 250 mg
Patients receive olaparib PO BID, and tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with olaparib continues for up to 12 months in the absence of disease progression or unacceptable toxicity. Treatment with tremelimumab repeats every 4 weeks for up to 4 courses and treatment with durvalumab repeats every 4 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity.
Durvalumab: Given IV
Patients are Platinum Sensitive. Laboratory Biomarker Analysis: Correlative studies
Olaparib: Given PO
Tremelimumab: Given IV
Patients are Platinum Sensitive
Deaths Number Affected:
4
Deaths Number At Risk:
None
Serious Number Affected:
7
Serious Number At Risk:
10
Other Number Affected:
9
Other Number At Risk:
10
Study:
NCT02953457
Results Section:
NCT02953457
Adverse Events Module:
NCT02953457